Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients
During the first two years of the project duration the curative anti-tumorous combined
treatment in fertile patients with Hodgkin disease diagnosis will be carried out. Patients
are to be divided into three groups according to the clinical stage of the disease and
treated with the three types of the chemotherapeutic regimens comparable with toxicity.
Patients will receive GnRH analogues during the chemotherapy for the gonadal protection by
the mechanism of foliculogenesis inhibition in pre-pubertal stage. At the end of successful
treatment according to stated criteria the ovarian function of every patient will be
repeatedly evaluated in relation with toxicity of chemotherapy used. These ovarian function
results will be compared with control group of patients without gonadal protection, which
reproductive functions will be evaluated according the same method.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Premature ovarian failure after chemotherapy
Premature ovarian failure defined as levels of FSH over 15 IU/l in peripheral blood.
6 months after the end of chemotherapy
Martin Huser, MD, PhD
Czech Republic: Grant Agency of the Ministry of Health